That’s a good summary of the LFB collaboration. However, it fails to mention that the first product launch arising from the collaboration won’t happen until circa 2013.
The fact that the fruits of this collaboration are so far into the future is one of the reasons the market hasn’t reacted favorably to the deal, IMO. (Dilution, of course, is another reason.)
GTC needs to ink more Merrimack-like supply deals. These deals don’t have to be terribly creative—they merely have to bring in some revenue while we wait for the bigger payoffs from ATryn approval in the U.S., the ATryn program in DIC/sepsis with Leo Pharma, and the Factor VIIa program with LFB.
Market Data 
Markets 
AI
